These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34563992)

  • 21. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma.
    Jaeger HJ; Mehring UM; Castañeda F; Hasse F; Blumhardt G; Loehlein D; Mathias KD
    Cardiovasc Intervent Radiol; 1996; 19(6):388-96. PubMed ID: 8994703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.
    Yuen MF; Chan AO; Wong BC; Hui CK; Ooi GC; Tso WK; Yuan HJ; Wong DK; Lai CL
    Am J Gastroenterol; 2003 May; 98(5):1181-5. PubMed ID: 12809846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
    Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.
    Cabibbo G; Genco C; Di Marco V; Barbara M; Enea M; Parisi P; Brancatelli G; Romano P; Craxì A; Cammà C
    Aliment Pharmacol Ther; 2011 Jul; 34(2):196-204. PubMed ID: 21564144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
    Tong H; Wei B; Chen S; Xie YM; Zhang MG; Zhang LH; Huang ZY; Tang CW
    Oncotarget; 2017 Jul; 8(29):48303-48312. PubMed ID: 28430638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.
    Biselli M; Andreone P; Gramenzi A; Trevisani F; Cursaro C; Rossi C; Ricca Rosellini S; Cammà C; Lorenzini S; Stefanini GF; Gasbarrini G; Bernardi M
    Clin Gastroenterol Hepatol; 2005 Sep; 3(9):918-25. PubMed ID: 16234031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival.
    Han K; Kim JH; Yoon HM; Kim EJ; Gwon DI; Ko GY; Yoon HK; Ko HK
    Korean J Radiol; 2014; 15(4):464-71. PubMed ID: 25053906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma.
    Meyer T; Kirkwood A; Roughton M; Beare S; Tsochatzis E; Yu D; Davies N; Williams E; Pereira SP; Hochhauser D; Mayer A; Gillmore R; O'Beirne J; Patch D; Burroughs AK
    Br J Cancer; 2013 Apr; 108(6):1252-9. PubMed ID: 23449352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
    Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
    JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma.
    Kim DY; Ryu HJ; Choi JY; Park JY; Lee DY; Kim BK; Kim SU; Ahn SH; Chon CY; Han KH
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1343-50. PubMed ID: 22486716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
    Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial.
    Yang M; Fang Z; Yan Z; Luo J; Liu L; Zhang W; Wu L; Ma J; Yang Q; Liu Q
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):211-9. PubMed ID: 24374800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
    Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
    Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Zhou B; Yan Z; Liu R; Shi P; Qian S; Qu X; Zhu L; Zhang W; Wang J
    Radiology; 2016 Aug; 280(2):630-9. PubMed ID: 26885681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma.
    Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Nakano M; Okamura S; Noda Y; Kamachi N; Sakai M; Suzuki H; Nomiyama M; Kuromatsu R; Koga H; Torimura T
    Oncology; 2020; 98(8):558-565. PubMed ID: 32422633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.